Antibody Drug Conjugates (ADC) is a type of biopharmaceutical drug that combines a monoclonal antibody with a drug to treat cancer. ADCs are composite of three components: A monoclonal antibody that binds to specific proteins on cancer cells, A chemical linker that joins the antibody to the drug, and the drug payload that is released inside the cancer cell to kill it. Unlike chemotherapy, ADCs are designed to target cancer cells while minimizing damage to healthy cells.
A list of FDA approved and clinical trial ADCs are provided as a reference for customer's new ADC research & development. These ADC references can be used as a positive control for in vitro and in vivo studies.